Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Methenamine hippurate EQL Pharma approved

EQL Pharma
Read the release

Methenamine hippurate EQL Pharma is a pharmaceutical that is taken as a prophylaxis against recurrent urinary tract infections.

Methenamine hippurate EQL Pharma contains methenamine, a substance that has been registered in Sweden since 1973. Methenamine hippurate EQL Pharma becomes the first and only generic available on the markets where it is registered. The market for methenamine 1g tablet is medium sized in the countries concerned with about 35.5 MSEK in total annual sales, of which about half is in the UK

The product is expected to be launched during the fourth quarter, 2019.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.